Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Zhigang Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8965-223X; OpenAlex author ID A5100373986, A5130221098. Sources: OpenAlex.

Their work

Papers
53 (first author 0, last author 14)
Trials
0
Grants
0
Labs led
1
Collaborators
125
Papers, trials and grants by year

2014: 1 paper · 2015: 3 papers · 2016: 2 papers · 2017: 5 papers · 2018: 2 papers · 2019: 6 papers · 2020: 8 papers · 2021: 8 papers · 2022: 2 papers · 2023: 5 papers · 2024: 2 papers · 2025: 6 papers · 2026: 3 papers

Papers 50 of 53

  1. A cholesterol-dependent LRRC8A-caveolin-1 axis sustains KRAS/EGFR signaling, ribosome biogenesis and growth in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-026-03864-z↗
  2. Adipogenic transdifferentiation reprograms EMT-high PDAC cells into a post-mitotic adipocyte-like state and limits metastasis. Co-author DOI 10.1038/s41419-026-08613-4↗
  3. Retraction: Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer. Co-author DOI 10.18632/oncotarget.28909↗
  4. Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy. Co-author DOI 10.1001/jamaoncol.2025.0460↗
  5. Reciprocal tumor-platelet interaction through the EPHB1-EFNB1 axis in the liver metastatic niche promotes metastatic tumor outgrowth in pancreatic ductal adeno… Co-author DOI 10.1002/cac2.12637↗
  6. Vitamin K-dependent gamma-carboxyglutamic acid protein 1 promotes pancreatic ductal adenocarcinoma progression through stabilizing oncoprotein KRAS and tyrosin… Co-author DOI 10.1002/ctm2.70191↗
  7. Histone serotonylation promotes pancreatic cancer development via lipid metabolism remodeling. Co-author DOI 10.1038/s41467-025-61197-z↗
  8. B4GALT5 inhibits CD8+ T-cell response by downregulating MHC-I level through ERAD pathway in PDAC. Co-author DOI 10.1136/jitc-2024-010908↗
  9. OASL promotes immune evasion in pancreatic ductal adenocarcinoma by enhancing autolysosome-mediated degradation of MHC-I. Co-author DOI 10.7150/thno.103494↗
  10. Development of a Serum-Based MicroRNA Signature for Early Detection of Pancreatic Cancer: A Multicenter Cohort Study. Co-author DOI 10.1007/s10620-024-08338-4↗
  11. Corrigendum to "Aberrant upregulation of KLK10 promotes metastasis via enhancement of EMT and FAK/SRC/ERK axis in PDAC." [Biochem. Biophys. Res. Commun. 499 (3… Last author DOI 10.1016/j.bbrc.2023.149426↗
  12. The genomic, transcriptomic, and immunological profiles of perineural invasion in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s11427-022-2146-5↗
  13. Transglutaminases are oncogenic biomarkers in human cancers and therapeutic targeting of TGM2 blocks chemoresistance and macrophage infiltration in pancreatic … Co-author DOI 10.1007/s13402-023-00824-7↗
  14. METTL3 suppresses pancreatic ductal adenocarcinoma progression through activating endogenous dsRNA-induced anti-tumor immunity. Co-author DOI 10.1007/s13402-023-00829-2↗
  15. Phase 1 Dose Escalation Study of SBRT Using 3 Fractions for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2023.03.036↗
  16. Coadaptation fostered by the SLIT2-ROBO1 axis facilitates liver metastasis of pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41467-023-36521-0↗
  17. Modeling of cancer-related body-wide effects identifies LTB4 as a diagnostic biomarker for pancreatic cancer. Last author DOI 10.1016/j.ebiom.2022.104050↗
  18. A low amino acid environment promotes cell macropinocytosis through the YY1-FGD6 axis in Ras-mutant pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-021-02159-9↗
  19. Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer. Co-author DOI 10.1001/jamaoncol.2021.0057↗
  20. Single-cell RNA sequencing reveals that targeting HSP90 suppresses PDAC progression by restraining mitochondrial bioenergetics. Co-author DOI 10.1038/s41389-021-00311-4↗
  21. Reciprocal regulation of LOXL2 and HIF1α drives the Warburg effect to support pancreatic cancer aggressiveness. Co-author DOI 10.1038/s41419-021-04391-3↗
  22. Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis. Last author DOI 10.1038/s41467-020-20447-y↗
  23. Increased Nuclear Transporter KPNA2 Contributes to Tumor Immune Evasion by Enhancing PD-L1 Expression in PDAC. Last author DOI 10.1155/2021/6694392↗
  24. Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic duc… Co-author DOI 10.1186/s13059-020-02222-w↗
  25. Deciphering the genomic and lncRNA landscapes of aerobic glycolysis identifies potential therapeutic targets in pancreatic cancer. Co-author DOI 10.7150/ijbs.49243↗
  26. The short isoform of PRLR suppresses the pentose phosphate pathway and nucleotide synthesis through the NEK9-Hippo axis in pancreatic cancer. Last author DOI 10.7150/thno.51712↗
  27. Duration of therapy for locally advanced pancreatic cancer: Does it matter? Co-author DOI 10.1002/cam4.3081↗
  28. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study. Co-author DOI 10.1016/j.ebiom.2020.102767↗
  29. BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41556-019-0455-6↗
  30. Ikarugamycin inhibits pancreatic cancer cell glycolysis by targeting hexokinase 2. Co-author DOI 10.1096/fj.201901237r↗
  31. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-2689↗
  32. Exploring and validating the clinical risk factors for pancreatic cancer in chronic pancreatitis patients using electronic medical records datasets: three coho… Co-author DOI 10.21037/tcr.2019.11.49↗
  33. Cadherin 13 Inhibits Pancreatic Cancer Progression and Epithelial-mesenchymal Transition by Wnt/β-Catenin Signaling. Co-author DOI 10.7150/jca.37762↗
  34. Mitochondrial Protein UQCRC1 is Oncogenic and a Potential Therapeutic Target for Pancreatic Cancer. Co-author DOI 10.7150/thno.38704↗
  35. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer. Co-author DOI 10.1038/s41388-019-0701-1↗
  36. Transcription factor NFAT5 contributes to the glycolytic phenotype rewiring and pancreatic cancer progression via transcription of PGK1. Co-author DOI 10.1038/s41419-019-2072-5↗
  37. GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca2+ signalling in a GAB… Last author DOI 10.1136/gutjnl-2018-317479↗
  38. DKK2 Impairs Tumor Immunity Infiltration and Correlates with Poor Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2019/8656282↗
  39. Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis. Last author DOI 10.1158/1078-0432.ccr-18-2297↗
  40. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy. Last author DOI 10.21037/cco.2019.03.02↗
  41. Aberrant upregulation of KLK10 promotes metastasis via enhancement of EMT and FAK/SRC/ERK axis in PDAC. Last author DOI 10.1016/j.bbrc.2018.03.194↗
  42. IL22RA1/STAT3 Signaling Promotes Stemness and Tumorigenicity in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-17-3131↗
  43. Integrated expression profiling of potassium channels identifys KCNN4 as a prognostic biomarker of pancreatic cancer. Last author DOI 10.1016/j.bbrc.2017.10.072↗
  44. Expression of key mTOR pathway components in pancreatic ductal adenocarcinoma: A multicenter study for clinicopathologic and prognostic significance. Co-author DOI 10.1016/j.canlet.2017.02.036↗
  45. Structural diversity of anti-pancreatic cancer capsimycins identified in mangrove-derived Streptomyces xiamenensis 318 and post-modification via a novel cytoch… Co-author DOI 10.1038/srep40689↗
  46. Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection. Co-author DOI 10.1080/0284186x.2016.1245862↗
  47. Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. Co-author DOI 10.1080/0284186x.2017.1342863↗
  48. CXCL12-CXCR7 axis contributes to the invasive phenotype of pancreatic cancer. Co-author DOI 10.18632/oncotarget.11330↗
  49. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer. Co-author DOI 10.18632/oncotarget.6772↗
  50. Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1038/srep10575↗

Closest collaborators

The 25 strongest of 125 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shu‐Heng Jiang · 31 shared papers, 2014–2026 · strength 3.70
  2. Li-Peng Hu · 20 shared papers, 2017–2026 · strength 2.50
  3. Yongwei Sun · 23 shared papers, 2015–2024 · strength 2.31
  4. Xueli Zhang · 13 shared papers, 2019–2026 · strength 2.17
  5. Xiaomei Yang · 12 shared papers, 2015–2026 · strength 1.60
  6. Minwei Yang · 13 shared papers, 2016–2026 · strength 1.47
  7. Qing Li · 10 shared papers, 2018–2024 · strength 1.13
  8. Jian‐Yu Yang · 13 shared papers, 2015–2026 · strength 1.06
  9. Qin Yang · 9 shared papers, 2019–2023 · strength 1.04
  10. Aziguli Tulamaiti · 4 shared papers, 2025–2026 · strength 0.94
  11. Dejun Liu · 9 shared papers, 2015–2023 · strength 0.90
  12. Yan‐Miao Huo · 10 shared papers, 2015–2026 · strength 0.89
  13. Linli Yao · 6 shared papers, 2021–2025 · strength 0.86
  14. Xu Wang · 7 shared papers, 2019–2023 · strength 0.83
  15. Rongkun Li · 7 shared papers, 2014–2023 · strength 0.75
  16. Xin Xing · 5 shared papers, 2017–2025 · strength 0.72
  17. Shan Zhang · 4 shared papers, 2022–2025 · strength 0.72
  18. Lili Zhu · 5 shared papers, 2018–2024 · strength 0.71
  19. Rong Hua · 9 shared papers, 2015–2023 · strength 0.71
  20. Gary Guishan Xiao · 6 shared papers, 2019–2024 · strength 0.66
  21. Dong‐Xue Li · 3 shared papers, 2025 · strength 0.63
  22. Xueliang Fu · 6 shared papers, 2016–2026 · strength 0.60
  23. Carla Hajj · 5 shared papers, 2017–2025 · strength 0.59
  24. Abraham Jing-Ching Wu · 5 shared papers, 2017–2025 · strength 0.59
  25. Hui Nie · 5 shared papers, 2019–2025 · strength 0.59

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.